Gene Therapy Deals Up 1067% in 2026 — Here's the Data

Thirty-five gene therapy deals closed between March and September 2026 — a 1067% increase over the prior six-month period (September 2025 to March 2026), which produced just 3. This is not a blip. Big Pharma is repricing gene therapy risk downward after a string of durable clinical readouts, and the capital is following conviction rather than hype for the first time in the modality's commercial history.

The Data — Gene Therapy Deal Activity, Period over Period

A move from 3 to 35 deals in six months is the kind of inflection that resets baseline expectations for an entire modality. For context, gene therapy licensing 2026 activity has already exceeded full-year deal counts from 2023 and 2024 combined, when manufacturing uncertainties and Bluebird Bio's commercial struggles suppressed appetite across the sector.

What's Driving the Trend

Three forces converged to produce this surge, and none of them are temporary.

First, clinical durability data matured. The gene therapy programs generating deal interest in 2026 are not Phase I curiosities — they carry 3+ years of follow-up showing sustained transgene expression. This addresses the single largest objection pharma BD committees have raised since 2019: does the effect last? The answer, across a growing number of programs in hemophilia, ophthalmology, and now cardiovascular disease, is yes. That changes the NPV calculus fundamentally. Risk-adjusted peak sales models that previously applied 40–50% probability haircuts for durability are now running at 65–75% for programs with mature data.

Second, manufacturing scaled. CDMO capacity for AAV vectors expanded materially through 2025, with Catalent (now under Novo Holdings), Lonza, and multiple specialist CDMOs bringing online capacity that simply didn't exist 24 months ago. Cost-of-goods projections dropped 30–40% for several AAV serotypes, making gene therapy economics viable for indications beyond ultra-rare diseases. This is the unlock that enables deals like the Verve–Lilly cardiovascular gene therapy partnership — a program targeting a patient population in the millions, not thousands.

Third, Big Pharma pipeline anxiety hit gene therapy's sweet spot. AbbVie, Lilly, and others face well-documented LOE cliffs in the 2028–2031 window. Gene therapies — with their potential for one-time curative dosing and premium pricing — offer durable revenue that can backfill biologics erosion. The strategic logic finally aligns with the clinical and manufacturing reality. When all three legs of the stool stabilize simultaneously, you get a 1067% deal surge.

Notable Deals

The Verve–Lilly deal is the defining transaction of this cycle. A $1B upfront payment for a cardiovascular gene therapy program signals that Lilly views gene therapy as a platform for large-indication medicine, not a niche play. The $2.3B total deal value places it among the top gene therapy transactions ever. Lilly's willingness to pay a billion dollars upfront reflects both the strength of Verve's PCSK9 program data and Lilly's urgency to diversify beyond GLP-1 dominance before market saturation compresses margins.

Lilly's double-down with Engage Bio — two deals in consecutive days totaling ~$400M in combined TDV — underscores that this isn't a one-off. Lilly is building a gene therapy franchise from scratch, and they're acquiring it through licensing rather than M&A. That's a deliberate structural choice: licensing preserves optionality and limits downside exposure if individual programs fail, while still securing commercial rights to the winners.

The REGENXBIO–AbbVie deal is notable precisely because financial terms weren't disclosed. AbbVie has historically been disciplined about gene therapy exposure, and this partnership likely involves REGENXBIO's NAV vector technology platform rather than a single asset. Platform deals of this nature signal that the acquirer is thinking in decades, not product cycles.

MeiraGTx's $400M royalty financing with Oberland Capital is a different animal — it's a non-dilutive capital raise backed by gene therapy revenue streams, not a traditional pharma license. The fact that royalty investors are now underwriting gene therapy cash flows at this scale tells you the market has moved past the "will this work?" phase into "how do we optimize the financial structure?" That's maturity.

What This Means for BD Teams Right Now

This is a seller's market for gene therapy assets with clinical durability data — full stop. If you have a gene therapy program with 2+ years of follow-up showing sustained expression, your leverage is higher today than at any point since the 2019 Spark–Roche acquisition. Gene therapy deal trends 2026 confirm that Big Pharma is competing for assets, and competition compresses timelines and inflates terms.

If you're selling: Push for larger upfronts. The Verve deal reset the benchmark — $1B upfronts are now within range for programs targeting large patient populations with strong Phase II data. Use Deal Benchmarks to anchor your negotiations against the current market, not last year's comps. Structure your term sheets to capture upside through tiered royalties rather than trading equity for certainty. Pharma buyers are willing to pay premium royalty rates to secure exclusive rights in this environment.

If you're buying: Move fast. The window where gene therapy assets trade at a discount to their intrinsic value is closing. The 1067% deal surge means your competitors are already running processes on the assets you're diligencing. Waiting six months for another data readout might cost you the deal entirely. Consider platform-level partnerships (like the REGENXBIO–AbbVie model) as a way to secure multiple shots on goal without overpaying for individual programs.

Deal structures shifting: Gene therapy licensing 2026 is trending toward higher upfronts and lower milestone-to-upfront ratios compared to 2024. The Verve deal's $1B upfront on a $2.3B TDV represents a 43% upfront-to-TDV ratio — well above the historical gene therapy average of 15–25%. Expect this ratio to compress slightly as more mid-stage assets enter the market, but the directional shift toward front-loaded economics is structural, not cyclical. Royalty financing structures (as seen in MeiraGTx–Oberland) are also gaining traction for companies that want capital without dilution or pharma entanglements.

Benchmark your deal against current market rates using the Ambrosia calculator. The gene therapy deal environment has shifted dramatically in six months — your 2025 comps are already outdated.